Penrose TherapeuTx, a privately held preclinical stage small molecule drug development company based in Ann Arbor and Boston, announced the appointment of David Sherris as its president and CEO.
“With Dr. Sherris’s drug development skills, his experience in business development and securing funding for biotechnology companies, we feel confident that he will bring Penrose TherapeuTx to its next phase of success,” says Mark de Souza, CEO and board member of parent company Tribar Healthcare Partners. “We are pleased to bring on such an accomplished scientist and biotech entrepreneur.”
Sherris has more than 30 years in translational medicine involving basis research, pharmaceuticals, and diagnostics, and has held numerous senior roles at companies including Serono, Centocor, Unilever Research, and Mateon Therapeutics.
In these roles, he has led the development of novel therapies from the bench to the clinic. He has published multiple scientific papers and holds patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease.
“I’m excited to lead such an innovative biotechnology company and work with the talented team dedicated to advancing Penrose’s mitochondrial modifying agents. A first-in-class, small molecule drug technology attacking tumor cells leading to their necrotic death is an exciting and novel means to tackle cancer,” says Sherris.
“I am grateful for the excellent work Mr. de Souza has done in his role establishing a solid foundation for the company. I’m committed to working with the Penrose team, the U.S. Food & Drug Administration and other global regulatory agencies to bring this technology into the next stage of clinical development and ultimately to the market.”